Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
#3PRI RANKED
Most Cited Paper
in Hepatocellular Carcinoma Treatment and Prognosis
18 Months Post-Publication
Class of 2026
“Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026/
Topics
Hepatocellular carcinoma · Advanced hepatocellular carcinoma · Systemic therapy · Atezolizumab plus bevacizumab · Durvalumab plus tremelimumab · sorafenib · lenvatinib · nivolumab + ipilimumab · pembrolizumab · nivolumab · durvalumab · cabozantinib · regorafenib · ramucirumab · Tyrosine kinase inhibitor · Immune checkpoint inhibitor therapy · alpha-fetoprotein · Child-Pugh class · Performance status · First-line treatment · Second-line therapy · third-line therapy · Randomized controlled trial · ASCO guideline · Clinical practice guidelines · PD-1/PD-L1 inhibitor · CTLA-4 inhibition · VEGF inhibition · liver disease · systematic review
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459